Atlas Brown Inc. maintained its position in shares of Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent filing with the SEC. The firm owned 3,741 shares of the insurance provider’s stock at the end of the second quarter. Atlas Brown Inc.’s holdings in Humana were worth $900,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Baldwin Brothers Inc. MA raised its stake in shares of Humana by 2.7% in the first quarter. Baldwin Brothers Inc. MA now owns 67,441 shares of the insurance provider’s stock worth $13,902,000 after buying an additional 1,782 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in shares of Humana by 1.3% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,308,615 shares of the insurance provider’s stock worth $266,997,000 after buying an additional 16,279 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock worth $3,566,000 after buying an additional 2,356 shares in the last quarter. Capstone Asset Management Co. raised its stake in shares of Humana by 2.0% in the first quarter. Capstone Asset Management Co. now owns 16,805 shares of the insurance provider’s stock worth $3,464,000 after buying an additional 334 shares in the last quarter. Finally, CHURCHILL MANAGEMENT Corp bought a new stake in shares of Humana during the second quarter worth $6,074,000. 99.66% of the stock is currently owned by institutional investors.
Humana Inc. (NYSE HUM) traded down 0.67% during midday trading on Friday, hitting $249.99. 840,299 shares of the stock traded hands. The stock’s 50-day moving average price is $239.62 and its 200-day moving average price is $222.88. The stock has a market capitalization of $36.13 billion, a P/E ratio of 20.57 and a beta of 0.91. Humana Inc. has a 52 week low of $163.50 and a 52 week high of $255.27.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter last year, the company earned $2.30 EPS. Equities research analysts expect that Humana Inc. will post $11.55 EPS for the current fiscal year.
A number of analysts have weighed in on the stock. UBS AG restated a “neutral” rating and issued a $237.00 target price (up previously from $205.00) on shares of Humana in a research report on Wednesday, June 28th. Cantor Fitzgerald reiterated a “neutral” rating and set a $223.00 price target (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Jefferies Group LLC reiterated a “hold” rating and set a $257.00 price target on shares of Humana in a report on Friday, August 4th. Zacks Investment Research lowered shares of Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, Piper Jaffray Companies lifted their price target on shares of Humana to $280.00 and gave the stock an “overweight” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $243.65.
In other news, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction on Friday, May 26th. The stock was sold at an average price of $231.96, for a total value of $347,940.00. Following the transaction, the vice president now owns 8,150 shares in the company, valued at approximately $1,890,474. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.